# A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

> **NCT06104553** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 132 (estimated)

## Conditions studied

- B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** SHR-A1912; R-Chemo
- **DRUG:** SHR-A1912; R-Chemo

## Key facts

- **NCT ID:** NCT06104553
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-17
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06104553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06104553, "A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06104553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*